diabetes treatment
Canada Backs Aspect Biosystems With $280M to Scale Bioprinted Tissue Therapies
The Government of Canada is supporting bioprinting company Aspect Biosystems with a new $280 million project to help develop and manufacture its bioengineered cellular medicines. The project will run over…
Aspect Biosystems Expands Novo Nordisk Partnership, Signaling Broader Pharma Interest
Aspect Biosystems and Novo Nordisk are expanding their partnership. The duo had previously made a deal worth up to $2.6 billion in 2023. Then the deal centered on drug discovery…
Diabetes Treatment Gets Sci-Fi Upgrade with 3D Printed Microdevice Eye Implant
In a revolutionary step forward, researchers have 3D printed a biohybrid microstructure designed specifically for diabetes treatment. This innovation, stemming from a collaboration between the KTH Royal Institute of Technology…
Aspect Biosystems Strikes $2.6B Bioprinted Tissue Deal with Novo Nordisk
Bioprinting collaborations are heating up in 2023. In one of the biggest moves of the bioprinting industry, Canadian startup Aspect Biosystems and Danish pharma giant Novo Nordisk (CPH: NOVO-B) struck…
Can Fluicell’s Bioprinted Tissue Help Treat Type 1 Diabetes?
As Swedish bioprinter manufacturer Fluicell prepares to enter the regenerative medicine market through its BioRej Advance program, it focuses on developing therapeutic products based on bioprinted transplantable microtissues targeting important…
ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device
ROKIT Healthcare has completed registration of its Dr. INVIVO-based diabetic foot treatment with the U.S. FDA and has successfully completed clinical studies in the U.S. Since 2019, the company has…
